

IMPORTANT SAFETY INFORMATION FOR PATIENTS

DO

- Keep this card with you at all times
- Show this card to any doctor or pharmacist involved in your treatment
- Keep a list of all medications with you when you visit your doctor or pharmacist
- If you experience any unusual symptoms, like strange thoughts, including thoughts of hurting others, whilst taking Sodium Oxybate 500 mg/ml oral solution, inform your doctor straight away
- Store Sodium Oxybate 500 mg/ml oral solution away from children

Date first prescribed Sodium Oxybate 500 mg/ml oral solution

CONTACT INFORMATION

Patient's name:

Patient's telephone number:

Next of Kin name:

Next of Kin telephone number:

Treating doctor's name:

Doctor's phone number:

Contact number for emergency medical assistance:

IMPORTANT SAFETY INFORMATION FOR PATIENTS

Sodium Oxybate 500 mg/ml oral solution can depress breathing and consciousness.

DO NOT do any of the following:

- Do NOT take alcohol whilst being treated with Sodium Oxybate 500 mg/ml oral solution
- Do NOT take more than the dose prescribed by your doctor
- Do NOT drive or operate machinery within 6 hours of taking Sodium Oxybate 500 mg/ml oral solution
- Do NOT take any other medications unless you have discussed these with your doctor
- Do NOT share your Sodium Oxybate 500 mg/ml oral solution with anyone else.

IMPORTANT SAFETY INFORMATION FOR PHYSICIANS/PHARMACISTS

This patient is taking Sodium Oxybate 500 mg/ml oral solution for the treatment of narcolepsy with cataplexy.

Sodium Oxybate 500 mg/ml oral solution can cause respiratory and CNS depression, seizures, psychotic events, depression and suicidality.

Opioids or barbiturates should not be used with Sodium Oxybate 500 mg/ml oral solution. Other respiratory and CNS depressants should be avoided. Be specifically careful using topimaratate and valproate with Sodium Oxybate 500 mg/ml oral solution.

Sodium Oxybate 500 mg/ml oral solution has the potential for abuse/misuse/dependency.

Please refer to the SmPC for Sodium Oxybate 500 mg/ml oral solution before prescribing/dispensing other drugs for this patient.

Call for reporting

Healthcare providers and patients are encouraged to report suspected adverse reactions associated with the use of sodium oxybate. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Zentiva Pharma UK Limited. e-mail: ukmedinfo@zentiva.com. If you require any more materials please contact ukmedinfo@zentiva.com.

